A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)
Status:
Terminated
Trial end date:
2019-08-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and
pharmacodynamics (PD) of CT053PTSA in Relapsed/refractory AML patients with FLT3 gene
mutation.